Co-Olmepress 40mg/25mg Tablets / Film-coated
Hydrochlorothiazide + Olmesartan Medoxomil
"40mg, 25mg"
Laboratorios Cinfa S.A
| Pack size | 28 Tablets |
|---|---|
| Dispensing mode | POM |
| Source | SPAIN |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 53.50 AED |
Indications
Co-Olmepress 40mg/25mg Tablets / Film-coated is used for:
Hypertension, Diabetic nephropathy
Adult Dose
Hypertension
Initial: 20 mg/12.5 mg PO qDay
May increase to 40 mg/25 mg after 2 weeks
Hepatic Impairment
Dose adjustment not necessary
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment
CrCl <30 mL/min: Not recommended
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity to olmesartan medoxomil, hydrochlorothiazide or to other sulfonamide-derived drugs. Severe hepatic & renal impairment (CrCl <30 mL/min); cholestasis & biliary obstructive disorders; refractory hypokalemia; hypercalcemia; hyponatraemia, symptomatic hyperuricaemia; anuria. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). Pregnancy (2nd & 3rd trimester) & lactation.
Precautions
Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency.
Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.
Lactation: discontinue drug or do not nurse
Pregnancy-Lactation
Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)
Lactation: discontinue drug or do not nurse
Interactions
Olmesartan medoxomil: Increased risk of hypotension, hyperkalemia & changes in renal function w/ aliskiren. May result in deterioration of renal function w/ NSAIDs. May attenuate the antihypertensive effect of angiotensin II receptor antagonists. Reduces systemic exposure & peak plasma conc w/ colosevelam HCl.
Hydrochlorothiazide: Potentiation of orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs. Potentiation effect w/ other antihypertensives. Reduced absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroid, ACTH. Decreased response to pressor amines (eg norepinephrine). Increased responsiveness to skeletal muscle relaxants (eg tubocurarine). Reduce the renal clearance of lithium.
Adverse Effects
Side effects of Hydrochlorothiazide + Olmesartan Medoxomil :
1-10%
Olmesartan
Dizziness (3%), Headache (1%), Fatigue, Diarrhea (1%), Hyperglycemia (1%), Hypertriglyceridemia (1%), Back pain (1%), Bronchitis (1%), Flu-like symptoms (1%), Pharyngitis (1%), Rhinitis (1%), Sinusitis (1%), URI (1%)
Frequency Not Defined
Chest pain, Peripheral edema, Rash, Hyperuricemia, Dizziness, Hyperlipidemia, Diarrhea, Hyperuricemia, Hematuria, Hyperglycemia, Upper respiratory infections, Increased transaminases, Gastroenteritis, Dyspepsia, Arthralgia, Arthritis, Myalgia, Back pain, Increased CPK, Hydrochlorothiazide, Anorexia, Epigastric distress, Hypotension, Orthostatic hypotension, Photosensitivity, Anaphylaxis, Anemia, Confusion, Erythema multiforme, Stevens-Johnson syndrome, Exfoliative dermatitis including toxic epidermal necrolysis, Dizziness, Hypokalemia and/or hypomagnesemia, Hyperuricemia, Headache
Potentially Fatal: Acute renal failure.
Mechanism of Action
Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
Note
Co-Olmepress 40mg/25mg "40mg, 25mg" Tablets / Film-coated manufactured by Laboratorios Cinfa S.A. Its generic name is Hydrochlorothiazide + Olmesartan Medoxomil. Co-Olmepress 40mg/25mg is availble in United Arab Emirates.
Farmaco UAE drug index information on Co-Olmepress 40mg/25mg Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Hydrochlorothiazide + Olmesartan Medoxomil :
Tablets / Film-coated
Oxami H 20mg/12.5mg
"20mg, 12.5mg"
Neopharma
Tablets / Film-coated
Oxami H 40mg/12.5mg
"40mg, 12.5mg"
Neopharma
Tablets / Film-coated
Oxami H 40mg/25mg
"40mg, 25mg"
Neopharma
Tablets / Film-coated
Olmicard H 40/25
"40mg, 25mg"
Nexgen Pharma FZ LLC
Tablets / Film-coated
Olmicard H 40/12.5
"40mg, 12.5mg"
Nexgen Pharma FZ LLC